CervoMed's Participation in Upcoming Investor Conferences
CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, has announced that its management will participate in several important investor conferences this September. These events present a valuable opportunity for the company to share its latest developments and engage with the investment community.
Conference Details
Morgan Stanley 22nd Annual Global Healthcare Conference
The Morgan Stanley conference will feature a fireside chat format, fostering an engaging discussion about key initiatives and research advancements. This session is set for a Friday in September, and it will be open to all interested stakeholders.
H.C. Wainwright 26th Annual Global Investment Conference
After the Morgan Stanley event, CervoMed will also take part in the H.C. Wainwright conference. This corporate presentation will offer insights into the company's strategic direction and highlight ongoing developments related to its investigational therapies.
Webcast Information
Both presentations will be available via webcast, allowing investors and other interested parties to participate remotely. The webcasts will be accessible in the Investor section of the CervoMed website following the events.
About CervoMed and Neflamapimod
CervoMed Inc. is dedicated to providing innovative solutions for age-related neurologic disorders. The company’s leading investigational drug, neflamapimod, is an orally administered small molecule designed to effectively penetrate the brain. By inhibiting p38 mitogen-activated protein kinase alpha, neflamapimod aims to tackle synaptic dysfunction, a reversible factor associated with neurodegenerative diseases, including dementia with Lewy bodies (DLB).
This promising treatment is currently being evaluated in a Phase 2b study, specifically targeting early-stage DLB, and represents a significant step forward in the search for effective therapies in this area. The potential of neflamapimod has attracted considerable interest from both investors and medical professionals.
Investor Contact Information
For further inquiries, stakeholders can reach out to:
PJ Kelleher
LifeSci Advisors
Email: Investors@cervomed.com
Phone: 617-430-7579
Frequently Asked Questions
What is CervoMed's main focus?
CervoMed is dedicated to developing treatments for age-related neurologic disorders, with a particular focus on innovative therapeutic solutions.
What is neflamapimod?
Neflamapimod is an investigational drug from CervoMed that targets the inhibition of p38 mitogen-activated protein kinase alpha to address synaptic dysfunction.
When are the upcoming investor conferences?
The upcoming investor conferences are scheduled for September, with specific dates set for participation and presentations.
How can stakeholders access the webcasts?
The webcasts for the investor conferences will be available in the Investor section of the CervoMed website after the events conclude.
Who can be contacted for investor inquiries?
PJ Kelleher at LifeSci Advisors is available for investor-related inquiries via email at Investors@cervomed.com or by phone at 617-430-7579.